問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



China Medical University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,076

    Total Beds

  • 884

    Total Doctors

  • ctcadm.cmuh@gmail.com
  • Clinical Trial Center
  • 04-22052121#1471~1485
  • 404Taichung CityTaichung NorthNo. 2, Yude Rd., North Dist., Taichung City 404332, Taiwan (R.O.C.)

Recruiting Trial

693Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1743Cases

2026-06-01 - 2032-01-17

Phase III

Not yet recruiting
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

  • Condition/Disease

    Pancreatic Cancer、PDAC - Pancreatic Ductal Adenocarcinoma

  • Test Drug

    錠劑 靜脈輸注液 靜脈輸注液

Participate Sites
5Sites

Recruiting5Sites

2024-09-30 - 2028-11-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2024-10-01 - 2028-03-01

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2024-11-01 - 2029-08-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-11-01 - 2028-02-16

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2024-12-02 - 2027-12-31

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2024-11-27 - 2028-05-29

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-12-01 - 2028-08-18

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-12-01 - 2027-11-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-12-01 - 2024-12-02

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

1 19 20 21 22 23 175
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB